Pacira Pharma (PCRX) Tops Q3 Views

November 2, 2016 7:35 AM EDT
Get Alerts PCRX Hot Sheet
Trade PCRX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.22, $0.24 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $68.4 million versus the consensus estimate of $67.16 million.

2016 Outlook

Pacira updates its full year 2016 financial guidance as follows:

  • EXPAREL net product sales of $263 million to $268 million, reflecting management’s revised expectation about when its commercial strategies and creation of opioid-sparing collaborations will accelerate sales growth.
  • Non-GAAP gross margins of 70% to 73%.
  • Non-GAAP research and development (R&D) expense of $40 million to $50 million. This reduction in guidance reflects significant cost savings in three randomized clinical trials, along with a change in timing of some costs related to the two nerve block trials that the company expects to complete in the first quarter of 2017.
  • Non-GAAP selling, general and administrative (SG&A) expense of $125 million to $135 million.
  • Stock-based compensation of $30 million to $35 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities


Add Your Comment